Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years

Farhad Ravandi; Jörge E. Cortes; Stefan Faderl; Guillermo Garcia‐Manero; Susan O’Brien; Gautam Borthakur; Sherry Pierce; Mark Brandt; Marites Lang; Weiguo Zhang

doi:10.1182/blood.v112.11.768.768

Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years

Identifier:nobleid.org/w1/20260515/418FADC3

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/418FADC3.svg?ark=w1%2F20260515%2F418FADC3)](https://nobleid.org/work/w1/20260515/418FADC3)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Farhad Ravandi

Jörge E. Cortes

Stefan Faderl

Guillermo Garcia‐Manero

Claim authorship of this work

Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years

Identifier:nobleid.org/w1/20260515/418FADC3

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/418FADC3.svg?ark=w1%2F20260515%2F418FADC3)](https://nobleid.org/work/w1/20260515/418FADC3)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Farhad Ravandi

Jörge E. Cortes

Stefan Faderl

Guillermo Garcia‐Manero

Claim authorship of this work